MeiraGTx Holdings Overview
- Year Founded
-
2015

- Status
-
Public
- Employees
-
389

- Stock Symbol
-
MGTX

- Investments
-
5
- Share Price
-
$6.60
- (As of Thursday Closing)
MeiraGTx Holdings General Information
Description
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Contact Information
Website
www.meiragtx.comCorporate Office
- 450 East 29th Street
- 14th Floor
- New York, NY 10016
- United States
Corporate Office
- 450 East 29th Street
- 14th Floor
- New York, NY 10016
- United States
MeiraGTx Holdings Timeline
MeiraGTx Holdings Stock Performance
As of 13-Feb-2025, MeiraGTx Holdings’s stock price is $6.60. Its current market cap is $516M with 78.2M shares.
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$6.60 | $6.44 | $3.85 - $7.37 | $516M | 78.2M | 272K | -$1.20 |
MeiraGTx Holdings Financials Summary
As of 30-Sep-2024, MeiraGTx Holdings has a trailing 12-month revenue of $13.9M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 309,449 | 473,279 | 293,327 | 936,118 |
Revenue | 13,929 | 14,017 | 15,920 | 37,701 |
EBITDA | (64,866) | (59,330) | (116,843) | (70,885) |
Net Income | (88,177) | (84,027) | (129,615) | (79,561) |
Total Assets | 299,488 | 326,744 | 318,237 | 320,164 |
Total Debt | 86,735 | 89,264 | 92,248 | 23,733 |
MeiraGTx Holdings Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
MeiraGTx Holdings Comparisons
Industry
Financing
Details
MeiraGTx Holdings Competitors (6)
One of MeiraGTx Holdings’s 6 competitors is Axsome Therapeutics, a Corporation company based in New York, NY.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Axsome Therapeutics | Corporation | New York, NY | ||||
MediGene | Formerly VC-backed | Planegg, Germany | ||||
Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
Arcturus Therapeutics | Formerly VC-backed | San Diego, CA | ||||
Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
MeiraGTx Holdings Signals
MeiraGTx Holdings Investments & Acquisitions (5)
MeiraGTx Holdings’s most recent deal was a Merger/Acquisition with Bullseye Therapeutics for . The deal was made on 04-Oct-2021.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Bullseye Therapeutics | 04-Oct-2021 | Merger/Acquisition | Drug Discovery | ||
Visiogene (IP Rights Relating to Ocular Gene Therapy in Massachusetts, United States) | 04-Jan-2021 | Corporate Asset Purchase | Buildings and Property | ||
Emrys Bio | 09-Apr-2020 | Merger/Acquisition | Biotechnology | ||
Arthrogen | 17-Oct-2019 | Merger/Acquisition | Biotechnology | ||
Vector Neurosciences | 05-Oct-2018 | Merger/Acquisition | Biotechnology |
MeiraGTx Holdings ESG
Risk Overview
Risk Rating
Updated January, 30, 2024
28.94 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Biotechnology
Subindustry
of 368
Rank
Percentile

Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
Athena Brands | London, United Kingdom | 2015 |
MeiraGTx Holdings FAQs
-
When was MeiraGTx Holdings founded?
MeiraGTx Holdings was founded in 2015.
-
Where is MeiraGTx Holdings headquartered?
MeiraGTx Holdings is headquartered in New York, NY.
-
What is the size of MeiraGTx Holdings?
MeiraGTx Holdings has 389 total employees.
-
What industry is MeiraGTx Holdings in?
MeiraGTx Holdings’s primary industry is Biotechnology.
-
Is MeiraGTx Holdings a private or public company?
MeiraGTx Holdings is a Public company.
-
What is MeiraGTx Holdings’s stock symbol?
The ticker symbol for MeiraGTx Holdings is MGTX.
-
What is the current stock price of MeiraGTx Holdings?
As of 13-Feb-2025 the stock price of MeiraGTx Holdings is $6.60.
-
What is the current market cap of MeiraGTx Holdings?
The current market capitalization of MeiraGTx Holdings is $516M.
-
What is MeiraGTx Holdings’s current revenue?
The trailing twelve month revenue for MeiraGTx Holdings is $13.9M.
-
Who are MeiraGTx Holdings’s competitors?
Axsome Therapeutics, MediGene, Immunocore Holdings, Arcturus Therapeutics, and Inovio Pharmaceuticals are some of the 6 competitors of MeiraGTx Holdings.
-
What is MeiraGTx Holdings’s annual earnings per share (EPS)?
MeiraGTx Holdings’s EPS for 12 months was -$1.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »